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Inter-protein interactions govern protein loading
into porous vaterite CaCO3 crystals
Natalia A. Feoktistova,ab Nadezhda G. Balabushevich,a Andre G. Skirtach, c
Dmitry Volodkin ad and Anna S. Vikulina *b
The fast development of protein therapeutics has resulted in a high demand for advanced delivery
carriers that can effectively host therapeutic proteins, preserve their bioactivity and release them on
demand. Accordingly, vaterite CaCO3 crystals have attracted special attention as sacrificial templates for
protein encapsulation in micro- and nanoparticles (capsules and beads, respectively) under mild
biofriendly conditions. This study aimed to better understand the mechanism of protein loading into
crystals as a primary step for protein encapsulation. The loading of three therapeutic proteins (250 kDa
catalase, 5.8 kDa insulin, and 6.5 kDa aprotinin) was investigated for crystals with different porosities.
However, unexpectedly, the protein loading capacity was not consistent with the protein molecular
weight. It solely depends on the inter-protein interactions in the bulk solution in the presence of crystals
and that inside the crystals. The smallest protein aprotinin aggregates in the bulk (its aggregate size is
about 100 nm), which prohibits its loading into the crystals. Insulin forms hexamers in the bulk, which
can diffuse into the crystal pores but tend to aggregate inside the pores, suppressing protein diffusion
inward. Catalase, the largest protein tested, does not form any aggregates in the bulk and diffuses freely
into the crystals; however, its diffusion into small pores is sterically restricted. These findings are
essential for the encapsulation of protein therapeutics by means of templating based on CaCO3 crystals
and for the engineering of protein-containing microparticles having desired architectures.
1. Introduction
Since the commercialisation of recombinant human insulin as
the first therapeutic protein in 1982, the market of protein-
based drugs has become one of the most rapidly growing areas
in the pharmaceutical industry.1 Nowadays, several therapeutic
proteins belonging to different classes (monoclonal antibodies,
hormones, enzymes, growth factors, antimicrobial peptides,
etc.) are indicated for the treatment of multiple disorders,
including various cancers, diabetes, haemophilia, asthma, and
plaque psoriasis.2 As natural biological products, proteins are
selective, non-toxic and generally possess much lower side
effects than that usually caused by small-molecular-weight
drugs. However, to date, the therapeutic potential and wide
clinical use of protein-based therapeutics are largely limited by
their (i) high fragility resulting from their labile and micro-
environment-sensitive 3D structure and (ii) short half-life in the
blood stream, which is mostly caused by their fast degradation
by proteases.3,4 These obstacles can be circumvented via the
encapsulation of therapeutic proteins into delivery carriers
designed to preserve the structure and bioactivity of protein
molecules, protect them against enzymatic degradation, and
optionally achieve controlled and targeted protein delivery.5
Despite the existence of numerous drug delivery carriers, the
majority of them have been designed for the delivery of small-
molecular-weight drugs and the encapsulation conditions are
inappropriate for protein loading. This is due to the harsh
formulation conditions, which are harmful for protein bio-
activity (e.g., exposure to organic solvents), surface modification
and low encapsulation capacities.6,7 This has stimulated a high
demand for the development of sustainable nano- and micro-
particulate containers suitable for the mild encapsulation of
proteins.6,8,9
Accordingly, inorganic crystals of vaterite calcium carbonate
have attracted special attention from researchers.10,11 CaCO3 is
a low-soluble mineral that is abundant in nature12 and can be
easily synthesized by mixing precursor salts containing Ca2+
and CO3
2+ ions.13 Structurally, vaterite crystals are comprised of
a multitude of spherical nanocrystallines,13 which aggregate
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and form a highly developed mesoporous structure with an
average pore size in the range of 10–60 nm.14,15 This pore size is
ideal for the entrapment of large macromolecules with similar
dimensions. These crystals can be formulated in a wide range
of sizes starting from tens of nm16,17 up to tens of mm.18 The
shape of the particles also can be tuned.19 Importantly, although
the synthesis of CaCO3 is commonly performed in the presence
of organic solvents20 and polymer additives21–23 and various
stimuli24 can be used to control its pore size,9 recently the mild
way to produce vaterite CaCO3 crystals in aqueous media at a
pH close to near neutral (7–8) and ionic strength close to
physiological values has been proposed.13 Additionally, CaCO3
crystals are fully degradable and can be easily hydrolysed under
slightly acidic pH and in the presence of Ca2+-binding agents,
or recrystallised into more stable calcite polymorphs, changing
their porous structure to a non-porous one and releasing
encapsulated drugs.25,26 Recent studies also demonstrated the
high cellular uptake of CaCO3.
27,28 In addition, CaCO3 crystals
can be used as sacrificial templates for the formulation of
porous protein29 and polymer beads,30,31 and layer-by-layer
assemblies to produce multilayer capsules.32–35 All these findings
indicate that CaCO3 crystals are promising carriers for the encapsu-
lation of protein-based therapeutics for oral,36–38 intravenous,17
intratumoral,39 intranasal,40 and mucosal drug delivery;41,42 tissue
engineering43,44 and regeneration;45,46 and diagnostics.47,48 This
diversity of administration routes enabled by CaCO3 for protein
delivery is especially important because in current medical practice,
protein drugs are predominantly available in injectable formulations,
but the demand for non-invasive drug delivery systems for
therapeutic proteins is high.49
Despite the apparent potential of CaCO3 crystals for the
delivery of protein-based drugs, the inclusion of proteins inside
crystals largely remains unexplored. The twomain approaches for
the inclusion of the proteins in the solid matrix of CaCO3 are
co-synthesis (protein entrapment in CaCO3 during the formation
of the crystals) and adsorption (physisorption of proteins onto
pre-formed crystals).50 It is encouraging that regardless of the
loading approach, CaCO3 crystals have shown enormous loading
capacities for many therapeutic proteins, and furthermore the
bioactivity of the proteins after their release from CaCO3 crystals
remains high.51,52 Notably, co-synthesis often results in higher
loading efficiencies but lower residual protein activities.51,53
Nowadays it is widely believed that the adsorption of macromo-
lecules onto the porous surface of CaCO3 crystals is presumably
governed by electrostatic protein–CaCO3 interactions, which has
been proposed for polyelectrolytes,54,55 DNA56 and globular
proteins.57,58 Modulation of the strength of electrostatic inter-
actions via the doping of CaCO3 crystals with highly charged
polymer matrices has been reported to enhance protein
entrapment.59 Additionally, the impact of intermolecular inter-
actions on the adsorption and retention of macromolecules
inside the crystal pores has been clearly identified, but to date
this remains poorly understood.60 This is indicated by the number
of contradictory findings. For instance, the co-synthesis of catalase
into vaterite crystals resulted in the entrapment of a large amount
of this protein, which greatly exceeded the maximum possible
values calculated theoretically. This has been explained by protein
aggregation in the presence of Ca2+.53 Another demonstrative
example is the adsorption of the linear polymer poly(acrylic acid)
on the CaCO3 surface, which has been characterized by drastically
different Gibbs energies ranging from 45 kJ mol1 61 up to
+395 kJ mol1 62 in the corresponding studies. Importantly,
some studies report a direct correlation57 between the protein
net charge and adsorption capacities, while others report no
evidence of the correlations.50 Thus, the overall mechanism of
macromolecular loading in crystals remains unclear.
This study aimed to reveal the main factors responsible for
the protein loading in vaterite crystals, and therefore decipher
the mechanism of this type of protein loading. The role of the
inter-molecular interaction between threemodel globular proteins,
namely the enzyme catalase (CAT), the hormone insulin (INS), and
the proteinase inhibitor aprotinin (APR), was evaluated for protein
adsorption on vaterite crystals of different porosity, i.e. average
pore sizes of 10 and 15 nm. This was done by analysing the protein
diffusion in the crystals, protein distribution inside the crystals,
and protein aggregation state in solution. The chosen proteins
have different molecular masses and isoelectric points (pI),
allowing the impact of the physical–chemical characteristics of
the proteins on their loading into the crystals to be assessed as a
key to understand the loading mechanism. Besides, nowadays,
these proteins are widely used in medicine. Specifically, CAT is
an active component of gels applied for the healing of skin
ulcers and burns, INS is used to control blood sugar in diabetic
patients, and APR is used to decrease bleeding during surgeries
and treat some disorders. This makes them favorable candidates
for studying the protein interactions with vaterite carriers.
2. Experimental
2.1. Materials
Calcium chloride dihydrate CaCl22H2O, sodium carbonate
(Na2CO3, anhydrous), and fluorescein isothiocyanate isomer I
(FITC) were purchased from Sigma-Aldrich (Germany); aprotinin
from bovine lung: preparation ‘‘Ingiprol’’ (60% active centre)
from RUE Belmedpreparaty (Belarus); insulin, zinc salt from
Human Biosynthetic, IBCh RAS, Russia; and catalase from bovine
liver (C-1345) from Sigma, Germany. The water used in all
experiments was prepared using a Millipore Milli-Q purification
system and had a resistivity higher than 18.2 MO cm.
2.2. Synthesis of CaCO3 microcrystals
Porous vaterite CaCO3 microcrystals were prepared by rapidly
mixing an equal volume of aqueous solutions of CaCl2 and
Na2CO3 at two different temperatures according to the protocols
described elsewhere.13 Briefly, 3 mL of 1 M CaCl2 was added to
9 mL of water with constant stirring at a temperature of 22 1C or
45 1C. Then 3 mL of 1 M Na2CO3 (1 M) was rapidly added to this
solution at 22 1C or 45 1C, respectively. After vigorous agitation
with a magnetic stirrer (30 s, 160 rpm) and incubation for 15 min
at the corresponding temperature, the precipitate was filtered,
washed with water and dried at 80 1C.
Paper PCCP
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
4 
A
pr
il 
20
20
. D
ow
nl
oa
de
d 
on
 6
/2
9/
20
20
 8
:5
8:
39
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©the Owner Societies 2020 Phys. Chem. Chem. Phys., 2020, 22, 9713--9722 | 9715
2.3. FITC-conjugation of proteins
0.1 mg mL1 FITC solution in 0.5 M carbonate buffer (pH 9.0)
was added dropwise to 2 mg mL1 protein solution in the same
buffer under stirring to obtain the FITC : protein molar ratio of
1 : 5. The prepared solutions were incubated for 4 h in the dark
and placed in dialysis bags with a cutoff 8–10 kDa. Then dialysis
against water was conducted for all the protein solutions for
2 days. The obtained proteins solutions were stored at 20 1C.
2.4. Confocal laser scanning microscopy (CLSM)
CLSM analysis was performed using a Zeiss LSM 510 Meta
(Zeiss, Germany) equipped with an oil-immersion objective
with 40magnification and numerical aperture of 1.3. Standard
filter settings for excitation and emission of FITC were used for
a laser source with a wavelength of 488 nm. To study the protein
interaction with CaCO3 microcrystals, 0.2 mL of 1 mg mL
1
FITC-labelled protein solution (insulin-FITC, aprotinin-FITC, or
catalase-FITC) was added to 1 mg of microcrystals followed by
short agitation. Kinetic study of the protein accumulation was
performed bymonitoring the fluorescence signal inside the crystals.
Images were processed using Image PRO (Adobe Systems Inc) to
optimise brightness and colour.
2.5. Dynamic light scattering (DLS)
1 mg mL1 protein solution in water (pH 10.5) or in the
supernatant of the CaCO3 microcrystals was used for DLS
measurements using a Zeta-sizer Nano ZS (Malvern, UK). The
supernatant was prepared by dispersing 15 mg of CaCO3
microcrystals in 1 mL of water followed by 15 min incubation
and centrifugation to completely precipitate the crystals. The
protein solutions were filtered through a 0.22 mm filter before
the measurements.
2.6. Scanning electron microscopy (SEM)
SEM images were recorded using a Gemini LEO 1550 electron
microscope at an accelerating voltage of 3 kV. Samples were
prepared by dropping the particle suspension on a glass slide
followed by 1 h drying at 90 1C and then sputtering with gold.
2.7. Brunauer, Emmett and Teller (BET) analysis
N2 adsorption–desorption analysis was performed using a
QUADRASORB SI-MP (Quantachrome Instruments, USA) at
77.3 K. Prior to measurement, the samples were degassed at
150 1C for 20 h. The Brunauer–Emmett–Teller (BET) theory and
the Barret–Joyner–Halenda model were used for the surface
area and pore-size distribution analysis, respectively.
2.8. Raman microscopy
The Raman spectra of the prepared CaCO3 crystals was measured
using a Raman microscope (CRM200, WITec, Ulm, Germany)
equipped with a piezo-scanner (P-500, Physik Insrtumente,
Karlsruhe, Germany) and a diode-pumped 785 nm NIR laser
excitation (Toptica Photonics AG, Graefelfing, Germany). The
laser beam was focused through a 100 (NA 0.95, Olympus)
objective. The spectra were acquired with a thermoelectrically
cooled CCD detector (DU401ABV, Andor, UK) behind a grating
(300 g mm1) spectrograph (Action, Princeton Instruments Inc.,
Trenton, Nj, USA) with a spectral resolution of 6 cm1.
2.9. Mathematical fitting
The experimental points for the kinetics of protein adsorption
were fitted with the models described below.
Pseudo-first order (PFO) kinetics:
Q = Qmax(1  exp(kt)) (1)
Pseudo-second order (PFO) kinetics:
Q ¼ kQmax
2t
1þ kQmaxt (2)
Pore diffusion model:
log log
1
1Q  m
C0
¼ log K þ a log t (3)
Hill equation:
Q ¼ Qmaxt
n
K þ tn (4)
where Q and t are the protein adsorption capacity and time, and
Qmax and k are the maximum adsorption capacity and rate
constant, respectively. Adsorption capacities were expressed in
terms of relative fluorescence signal (%), and maximum fluores-
cence (Qmax) was taken as 100%. Parameters Co and m in the pore
diffusion model are proportional to the initial concentration of
protein in solution and the concentration of CaCO3 crystals,
respectively. K, a (o1) and n are non-dimensional parameters in
the pore diffusion model and the Hill equation.
The goodness of the fit was assessed based on adjusted
R-squared coefficients.
3. Results and discussion
3.1. Protein state in solution
The role of the protein nature in protein loading/diffusion in
vaterite microcrystals was investigated using three model ther-
apeutic proteins with various sizes and different pI (CAT, INS,
and APR). CAT and INS have similar pI (about 5.4) but have
different molecular weights, where CAT (250 kDa) is much
heavier than INS (6 kDa). Additionally, the hydrodynamic
diameter of CAT (dh B 10.4 nm)
63 exceeds that of INS (dh B
2.7 nm)64 by about 3–4 times. INS and APR are very similar in
terms of molecular size (dhB 2.9 nm for APR);
65 however, APR
has much higher pI (10.5).
Since vaterite crystals are partially soluble in water (solubility
constant of 1.3 105 M)26 and prone to hydrolysis, the aqueous
suspension of the crystals has a pH of about 10.5. Therefore, in
the presence of the crystals, CAT and INS are positively charged
and APR possesses no charge.
Besides, the presence of Ca2+ and HCO3
/CO3
2 ions liberated
from the CaCO3 crystals may cause conformational changes in the
protein structure. accordingly, the potential role of these ions in
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protein aggregation was probed by comparing the DLS volume-
weighted size distribution profiles of the aqueous protein solutions
with the pH adjusted to 10.5 and protein solution in the super-
natant of the crystal suspension having the same pH (Fig. 1). The
average hydrodynamic diameters (dh) of CAT, APR, and INS in
water with pH 10.5 were found to be 7.7 1.5, 1.8 0.9, and 4.5
0.3 nm, respectively, which correlate well with the literature data.
Notably, INS was present in the form of a hexamer, which is typical
for this protein (dhB 5.1 nm).
66
The dh of the proteins in the presence of the crystal super-
natant is shown in Fig. 1b. CAT and INS remained stable and
had the same dh as that in water with pH 10.5. However, APR
was prone to strong aggregation, where the average dh of the
self-associated APR assemblies increased significantly to
ca. 70–80 nm. The rate of the aggregation of APR was very
high, as concluded from the analysis of the change in count
rate as a function of time (Fig. 2). The aggregation was followed
by sedimentation of the aggregates, and consequently, a
reduction in the intensity of the scattered light. The count rate
drastically decreased after 5 min of replacement of APR in the
supernatant solution of the crystals. In contrast, no significant
changes were observed for CAT and INS in the supernatant
compared to the water solution with pH 10.5. The increase in
the average dh of CAT by a factor of almost two indicates the
tendency of CAT to aggregate in the presence of the ions in the
supernatant due to the hydrolysis of the crystals.
To investigate the role of the pore dimensions on the protein
loading into the crystals, as described in the next section, two
batches of crystals possessing different porosity were used,
where the dimensions of the pore sizes:
(i) exceeded the average size of INS and CAT but remained
below the diameter of the APR aggregates and (ii) exceeded the
average size of INS but closely corresponded to the diameter of CAT.
3.2. CaCO3 microcrystals of different porosity
Vaterite CaCO3 microcrystals having different porosity were
prepared as described in our previous study13 by varying the
preparation temperature (22 1C and 45 1C). Both types of crystals
have a similar diameter of 10  2 mm, but differ in their
porosity. The BET analysis revealed that the total pore volume
of the crystals (Vp) is 9.7  102 mL g1 and 20.5  102 mL g1
for the crystals prepared at 22 1C and 45 1C, respectively.
Considering that the apparent (bulk) density of the crystals (r)
equals 2.54 g mL1 (Mineralogy Database), the relative porosity
of the crystals can be calculated using an equation:
e = rVp (5)
Therefore, the porosities of the crystals prepared at 22 1C and
45 1C were found to be 0.25 and 0.52, respectively. The pore
distribution analysis revealed that the crystals prepared at 45 1C
have larger pores compared to those prepared at 22 1C (average
pore size of about 15 nm and 10 nm, respectively).
Fig. 3a and b present the SEM images of the microcrystals
prepared at 22 1C and 45 1C, respectively. The shape of both
types of crystals is not ideally spherical, and their morphology
is rather flocky-like. These morphological features are typical
for large CaCO3 crystals (size exceeding 10 mm).
13,19 The crystals
were the vaterite polymorph of CaCO3, as proven by the Raman
microscopy analysis (Fig. 3c). The characteristic peaks of the
Fig. 1 Size distribution by volume of the proteins in aqueous solution with
the pH adjusted to 10.5 (a) and protein–FITC dissolved in the supernatant
of CaCO3 microcrystals at pH 10.5 (b) at 22 1C. All solutions had a
concentration of 0.1 mg mL1 and were filtrated through a 0.22 mm filter.
Fig. 2 Time dependence of count rate for protein–FITC exposed to the
supernatant of CaCO3 microcrystals at 22 1C.
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vaterite polymorph (double peaks at 265 and 302 cm1 and at
1075–1090 cm1) are marked by arrows, and no characteristic
peaks of calcite were observed.67
3.3. Protein distribution inside the crystals of different porosity
The equilibrium distribution of the proteins on the surface and
inside the CaCO3 microcrystals was probed by CLSM for the
crystals exposed to an aqueous solution of FITC-labelled proteins.
Notably, the significant difference in the refractive indices of water
and the crystals (1.55–1.65 and 1.33, respectively) prevented quan-
titative conclusions from being drawn regarding the protein
localization. In addition, the structure of the crystals is meso-
porous, which may induce undesirable optical effects. However, a
fluorescence signal from the FITC-labelled proteins was detected
for the crystals, meaning that the excitation light (wavelength
488 nm) could penetrate the porous crystals, which allowed us
to perform a semi-qualitative analysis.
Fig. 4 illustrates the CLSM images of the crystals after 1 h of
incubation in the protein solutions. CAT was evenly distributed
in the whole internal volume of the crystals with large pores
(15 nm) exceeding its dh value (Fig. 4b and d). In contrast, the
incubation ofB10 nm CAT into the crystals with a smaller pore
sizes (B10 nm) resulted in the nonhomogeneous distribution
of CAT, which only partially penetrated the internal volume of
the crystals and largely remained on the crystal surface (Fig. 4a
and c). The obvious explanation for this is that CAT fills the
larger pores and has diffusion limitations to enter the pores
that are smaller or comparable to its dh.
Fig. 3 SEM images of CaCO3 microcrystals prepared at 22 1C (a) and 45 1C
(b) in water. Scale bar is 4 mm. Insets show 8 zoomed surfaces of the crystals
within yellow rectangular areas. (c) Raman spectra of the microcrystals pre-
pared at 22 1C and 45 1C (the arrows point at characteristic picks of vaterite).
Fig. 4 Confocal images and fluorescence profiles taken across crystals
incubated for 60 min with proteins labelled by FITC. The crystals prepared
at 22 1C (left: a, c, e, g, i, and k) and 45 1C (right: b, d, f, h, j, and l) and have
average pore sizes of 10 and 15 nm, respectively. The proteins are catalase
(a)–(d), insulin (e)–(h), and aprotinin (i)–(l). Scale bar is 20 mm.
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The signal originating from CAT loaded in the crystals also
varied in each crystal. As can visually be concluded from the
images in Fig. 4a and b, the signal intensity of CAT varied more
between the crystals prepared at 22 1C than that at 45 1C,
respectively. This indicates that a fraction of large crystal pores
is distributed less uniformly among these crystals. It should be
noted that the florescence signal from the FITC-labelled CAT in
the crystals was much higher than that outside the crystals (in
bulk solution), indicating that the equilibrium shifted towards
CAT adsorption in the crystals. This is consistent with the high
free Gibbs energy (36 kJ mol1) reported for CAT loading into
crystals via adsorption.51
Surprisingly, INS was homogeneously distributed inside the
crystals with large 15 nm-sized pores (Fig. 4f and h), but the
protein did not penetrate inside the crystals having smaller
10 nm sized pores (Fig. 4e and g). Notably, although the
dimensions of a single INS hexamer are smaller than that of
CAT, the distribution of INS on the crystal surface/inside the
crystals greatly shifted towards the surface. This indicates a
different mechanism for the diffusion of CAT and INS into the
crystal pores, as described below.
It can be assumed that the diffusion of CAT is not limited by
the crystal pores being blocked by molecules of CAT, which is
expected due to very close values of the CAT diameter and the
average pore sizes of the crystals. CAT diffusion into the pores
did not induce any aggregation of the protein molecules in the
pores due to their proximity and potential unfolding, which
can enhance inter-protein aggregation. In the case of INS, the
mechanism differs. The INS molecules that enter the crystal
pores tended to aggregate with each other in the pores due to
the hydrophobic inter-protein attractions, which drive the
formation of INS hexamers. For the CAT molecules, this hydro-
phobic effect may not be so prominent and can be compensated
by electrostatic repulsion. It is known that INS is prone to the
formation of elongated amyloid-like aggregates upon contact
with hydrophobic surfaces. The diameter of these amyloid
aggregates is typically in the range of 2–5 nm with a length of
tens of nm. Thus, we assume that the formation of similar or
other types of INS aggregates in the pores or on the vaterite
surface may lead to the complete clogging of the smaller 10 nm
pores, but only partial blockage of the larger 15 nm pores. This
hypothesis is collaborated by the high Gibbs energy for amyloid INS
aggregation (26  8 kJ mol1),68 which is close to or exceeds that
for INS adsorption on the vaterite surface (27  1 kJ mol1).51
However, more evidence is required to explain the mechanism of
INS adsorption on CaCO3 crystals, which was not the main focus of
the present study.
Compared to the other tested proteins, APR had the lowest
affinity for the vaterite surface. That was confirmed by the
lowest ratio of the average fluorescence signal obtained from
the crystals to background fluorescence in solution. Thus, for
the crystals with 15 nm sized pores this ratio was found to be
31  7, 6  1 and 2  1 for INS, CAT and APR, respectively. The
aggregation of APR in the presence of crystals (Fig. 1) seriously
suppressed its diffusion into the crystals with a much smaller
size (Fig. 4i–l). Some of the signals detected inside the crystals
may be related to the presence of single molecules and APR
aggregates of smaller sizes.
Thus, the results above illustrate that protein diffusion
cannot be predicted based on the dh and pI of proteins. Hence,
for all three tested proteins, their adsorption on vaterite crystals
is thermodynamically favourable, but to varying degrees.51
Thus, to gain more insight into the protein interaction with
the crystals, the kinetics of protein loading into the crystals was
further investigated.
3.4. Kinetics of protein adsorption
Herein, the kinetics of protein loading into the crystals was
assessed by means of the relative fluorescence signal accumulated
in the vaterite crystals during the loading of FITC-labelled proteins
(Fig. 5). Notably, the absolute values of the fluorescence signals
cannot be compared because of the various and hardly evaluated
effects of the crystal internal microenvironment on the fluorescence
of the loaded proteins due to quenching. However, the shapes of the
normalized loading profiles can be compared to draw a conclusion
about the kinetics of the protein loading.
The different adsorption kinetics observed for the tested ther-
apeutic proteins indicate the existence of different adsorption
mechanisms. The results presented in Fig. 5 show that the time
when the protein signal reaches a plateau (equilibrium saturation)
was a couple of minutes for CAT, whereas saturation was not
reached for INS even after 30 min of loading. In the case of APR,
saturation was achieved after ca. 10 min of incubation.
Protein adsorption into porous matrices is usually limited
either by surface adsorption or molecular diffusion inside the
crowded porous matrix. Thus, the possible adsorption mechanism
and corresponding rate-controlling steps may be established by
applying kinetics models. The following models for the kinetics of
protein adsorption were applied in this study: (i) pseudo-first and
Fig. 5 Kinetics of the protein penetration in the particles for 30 min under
normal conditions by means of total normalized protein–FITC fluores-
cence intensity.
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(ii) pseudo-second order adsorptionmodels and (iii) pore diffusion
model. The adjusted R2 coefficient that considers the number of
parameters and the number of experimental points was used
for the validation of the models. Table 1 lists the fitting
parameters obtained for CAT, INS and APR. The best fitting
of the CAT adsorption kinetics to the PSO equation indicates
that CAT adsorbs on the vaterite surface via chemisorption. The
adsorption of INS is significantly slower, which may be related
to the lower affinity of INS to the crystal surface in comparison
with that of CAT (DG of 27 and 36 kJ mol1, respectively).51
This obeys the PFO equation, and therefore is driven by
physisorption.71
The low R2 coefficients obtained for both CAT and INS
indicate that pore diffusion is not the limiting step and the
proteins diffuse sufficiently fast inside the pores of the vaterite
crystals, causing the adsorption of the crystals to be the slowest
and rate-limiting step.
Interestingly, recently it has been shown that in contrast to
these proteins, the adsorption of mucin is controlled by its
retarded diffusion inside the pores of vaterite crystals.42 This
comparison indicates that the spreading dynamics of compact
globular proteins is less affected by their interaction with the
walls of the CaCO3 pores when compared to the large and non-
globular mucin, which is known for its strong adhesiveness.
Although accurate evaluation of the impact of the protein–wall
interactions on the actual law of diffusion of these proteins is
challengeable and has not been performed thus far (as has
been shown for the diffusion of other molecules in crowded
and non-inert matrices72,73), it can be assumed that these
specific interactions are not strong enough to be determinative
for the overall adsorption kinetics.
Moreover, considering the very similar pI of CAT and INS, it
may be assumed that the binding of CAT to the vaterite surface
is not electrostatic nature and is driven more by hydrophobic
and/or other specific interaction with CaCO3. Interestingly, it
has recently been demonstrated that the impact of van der
Waals forces is prevalent over electrostatic binding of CAT to
CaCO3 crystals.
74 Here, we demonstrate that the adsorption of
INS, which has a similar surface charge to that of CAT, is non-
specific, indicating that the electrostatic attraction of INS to
vaterite may not play a significant role.
Finally, the adsorption of APR corresponds to an S-shaped
curve, which indicates a much more complex mechanism of
adsorption involving surface clustering.69 Since the peculiar
S-shape of the APR loading kinetics could not be easily fitted to
any known kinetic models that have a solid mechanistic basis
(some of these models exist but require complex numerical
solutions),69 APR adsorption was fitted to the well-known
Hill equation.70 This equation is commonly applied for dose–
response curves, and therefore allows only some parameters to
be extracted, but not the rate constants (Table 1).
Remarkably, the inflection point for the APR adsorption
kinetics (8 min) corresponds well to the time needed for the
formation of APR aggregates (also about 8 min, Fig. 2). Specifically,
while APR is non-aggregated, it can diffuse inside the crystals.
Afterwards, APR heavily aggregates in the bulk solution and cannot
enter the pores of CaCO3 due to steric limitations. Meanwhile, the
large APR aggregates are not anchored to the external surface of
the crystals, and therefore do not block the pores (as confirmed
by the homogeneous APR distribution, as shown in Fig. 4). At
this stage (after inflection point in the kinetic curve), the
remaining single APR molecules continue to diffuse inside the
crystals until equilibrium between the single molecules, and
small and large aggregates of APR is reached in both the
solution and the crystal interior.
3.5. Mechanism of protein diffusion
Together with the state of the proteins and protein distribution
in the crystals assessed above, the characteristic kinetics for the
saturation of the crystal internal surface with the tested proteins
Table 1 Parameters of the mathematical fitting of the kinetics of APR, INS and CAT adsorption into the vaterite CaCO3 crystals (crystals have average
pore diameter of 10 nm) for four kinetic equations (eqn (1)–(4)): PFO, PSO, pore diffusion and Hill models
Protein Model Parameter Adj. R2 Insight to mechanism
CAT PFO k 0.90 min1 0.984 PSO chemisorption
PSO k 3.5  104%1 s1 0.994
Pore diffusion a 0.06 0.891
K 80.1
m/C0 0.011
Hill K 0.13; n 0.5 0.992
INS PFO k 0.14 min1 0.994 PFO physisorption
PSO k 4.3  105%1 s1 0.953
Pore diffusion a 0.4 0.507
K 25.6
m/C0 0.014
Hill K 10.5; n 1.5 0.980
APR PFO k 0.11 min1 0.881 Hill, S-shaped protein clustering
PSO k 3.0  105%1 s1 0.794
Pore diffusion a 0.6 0.301
K 16.5
m/C0 0.016
Hill K 3.7  105; n 6.5 0.994
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strongly supports the mechanism of the adsorption of the three
therapeutic proteins, as illustrated in Fig. 6.
CAT diffuses in the pores of the crystals without significant
steric limitations and strongly binds to the entire surface of
CaCO3 via chemisorption. The equilibrium is strongly shifted
towards the crystal volume (Fig. 6a).
INS does not aggregate in solution but tends to cluster at the
surface of the crystals, where it predominantly adsorbs on the
external surface of the CaCO3 crystals. The equilibrium is
shifted towards the formation of surface aggregates (Fig. 6b),
and thus its affinity to CaCO3 is much lower in comparison to
that of CAT.
In contrast, APR forms aggregates immediately in solution,
but these aggregates have a lower affinity to the crystal surface,
do not anchor the surface of the CaCO3 crystals, and do not
block the crystal pores, and therefore do not hinder the protein
diffusion inside the crystals. APR diffusion into the crystals
strongly depends on the aggregation kinetics, where the major
portion of APR fills the crystal pores when APR is not yet heavily
aggregated. Further adsorption results in more single APR
molecules and the formation of small APR aggregates (with
dh below the pore diameter) until equilibrium is reached
between the APR aggregates and single molecules in solution
and inside the crystals. Although the negative Gibbs free energy
value indicates favourable adsorption, its equilibrium constant
is much lower than that for CAT and INS adsorption, indicating
that most of the APR remains in the bulk solution (schemati-
cally shown with a double arrow in Fig. 6c).
4. Conclusions
Herein, the main factors responsible for protein loading into pre-
formed vaterite CaCO3 crystals were revealed. The mechanism of
the adsorption of three model therapeutic proteins of various
molecular masses and pI, i.e. CAT, INS, and APR, was proposed.
The protein loading does not directly correlate with the size and
the net charge of the proteins. For instance, the largest protein
CAT (250 kDa) showed better diffusion into the crystal pores;
however, the diffusion of the much smaller INS and APR (6 kDa)
was restricted by steric limitations. These limitations are caused
by Ca2+-mediated inter-protein aggregation in the presence of the
crystals, either in solution (APR) or on crystal surface (INS). For
the proteins that are prone to aggregation, molecular diffusion
into the pores is governed by the equilibrium constant of the
protein aggregation. In case of strong aggregation (INS) that
occurs only at the crystal surface, protein diffusion through the
crystal pores is sterically hindered. APR forms large aggregates of
ca. 80 nm initially in solution, but these aggregates do not anchor
to the crystal surface, and therefore do not block the pores and
hinder further diffusion. Single molecules of APR that are present
in equilibrium with the APR aggregates can freely diffuse into the
pores. Once the protein molecules penetrate the pores of the
vaterite crystals, they diffuse through the porous matrix quite
fast; however, the methods were used in this study did not allow
the estimation of the effective diffusion coefficients of the
proteins. Nevertheless, it was concluded that self-diffusion does
not determine the overall rate of protein adsorption. Instead,
protein adsorption is limited by surface processes. This study
strongly supports the pivotal role of inter-protein interaction in
solution and on the crystal surface in protein adsorption in
vaterite CaCO3. Thus, aggregation should be carefully considered
when encapsulating therapeutic proteins inside vaterite crystals.
Specifically, it may have a significant impact not only on the loading
but also on the release and preservation of the activity of the
therapeutics, which play a crucial role in drug delivery applications.
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